MRI Not Essential for All Biopsy-Naïve Prostate Cancer Patients: Multicenter Study Insights
Overview
This multicenter cohort study of 2714 biopsy-naïve men with prostate cancer evaluated the necessity of MRI prior to initial biopsy and compared combined biopsy (CB), systematic biopsy (SB), and MRI-targeted biopsy (TB). Findings showed CB had the highest cancer detection rates, but SB alone detected clinically significant prostate cancer (csPCA) comparably to TB, especially in PI-RADS 3 patients, suggesting MRI may not be essential for all patients.
Background
Accurate differentiation between clinically significant and non-significant prostate cancer is critical for treatment decisions. Multiparametric MRI with PI-RADS scoring improves detection and reduces overdiagnosis compared to systematic biopsy alone. However, MRI-targeted biopsy has limitations including technical challenges, variability in interpretation, and requires specialized expertise and infrastructure. Consequently, the negative predictive value of MRI is variable, and systematic biopsy remains important, especially in biopsy-naïve men.
Data Highlights
Parameter
Combined Biopsy (CB)
Systematic Biopsy (SB)
Targeted Biopsy (TB)
Overall Cancer Detection Rate (CDR)
Higher than SB and TB (p < 0.001)
91.3%
83.1%
Clinically Significant PCA Detection
72.7%
Similar to TB (p = 0.754)
Similar to SB (p = 0.754)
Non-significant PCA Detection
Not specified
30.7%
22.2% (8.6% less than SB, p = 0.001)
Efficiency (CDR per biopsy core)
Not specified
Lower than TB (p < 0.001)
Higher than SB (p < 0.001)
PI-RADS 3 csPCA Detection
Not specified
More frequent than TB (p = 0.001)
Less frequent than SB (p = 0.001)
PI-RADS 4 csPCA Detection
Not specified
Comparable to TB (p = 0.680)
Comparable to SB (p = 0.680)
PI-RADS 5 csPCA Detection
Not specified
Less frequent than TB (p = 0.002)
More frequent than SB (p = 0.002)
Key Findings
Combined biopsy (CB) showed significantly higher overall prostate cancer detection rates compared to systematic biopsy (SB) and targeted biopsy (TB) (p < 0.001).
SB detected clinically significant prostate cancer (csPCA) at rates similar to TB overall (p = 0.754), but detected more non-significant PCA than TB (30.7% vs. 22.2%, p = 0.001).
TB was more efficient per biopsy core taken for cancer detection than SB (p < 0.001).
In PI-RADS 3 patients, SB detected more csPCA than TB (p = 0.001); detection rates were comparable in PI-RADS 4 patients, while TB outperformed SB in PI-RADS 5 patients (p = 0.002).
In patients with PSA > 20 ng/ml, CB outperformed SB significantly (p < 0.001), but SB and TB had similar performance (p = 0.442).
Despite MRI's advantages, the study suggests MRI-targeted biopsy may not be essential for all biopsy-naïve men, especially those with lower PI-RADS scores.
Clinical Implications
Systematic biopsy remains a valuable diagnostic tool for detecting clinically significant prostate cancer, particularly in patients with PI-RADS 3 lesions where it may outperform MRI-targeted biopsy. Combined biopsy offers the highest detection rates but requires more resources. Given the variability in MRI performance and access limitations, clinicians should consider individual patient risk factors and resource availability when deciding on biopsy strategies, rather than relying solely on MRI prior to biopsy.
Conclusion
While combined biopsy yields the highest detection rates, systematic biopsy alone detects clinically significant prostate cancer comparably to MRI-targeted biopsy in many patients, especially those with lower PI-RADS scores. Therefore, MRI may not be essential for all biopsy-naïve men, supporting a tailored approach to prostate cancer diagnosis.
References
German Society of Residents in Urology Academics Multicenter Study 2024 -- Is MRI Essential for All Patients Without Prior Biopsy?
